La nausea ha colpito il 28,6% dei pazienti trattati con retatrutide 4 mg, il 38,4% con 9 mg e il 42,4% con 12 mg, contro il 14,8% del placebo
Furthermore, research indicates that lycopene positively modulates the activity of endothelial nitric oxide synthase (eNOS), the enzyme responsible for producing NO in the first place
(2023) Phase 2 Retatrutide Trial, NEJM (PubMed) Coskun et al
Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease
[1] [2] Additional important safety considerations include risk of pancreatitis, gallbladder disease, hypoglycemia (especially when used with insulin or sulfonylureas), and acute kidney injury associated with severe gastrointestinal adverse reactions